LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results